Addition of a dipeptidyl peptidase‐4 inhibitor, sitagliptin, to ongoing therapy with the glucagon‐like peptide‐1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

To determine whether the addition of sitagliptin to pre‐existing therapy with liraglutide changes glycaemic excursions after a mixed meal.

[1]  M. Nauck,et al.  Glucagon-like peptide 1 and its derivatives in the treatment of diabetes , 2005, Regulatory Peptides.

[2]  J. Holst,et al.  Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist , 2016, Diabetes.

[3]  Bo Ahrén,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .

[4]  T. Hughes,et al.  Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. , 2002, The Journal of endocrinology.

[5]  C. Kapitza,et al.  Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin , 2013, Diabetes, obesity & metabolism.

[6]  R. Hovorka,et al.  Measuring prehepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule , 1998, Diabetologia.

[7]  C. Mcintosh,et al.  Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY , 2006, Diabetologia.

[8]  Karen L Jones,et al.  Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. , 2010, The Journal of clinical endocrinology and metabolism.

[9]  V. Fonseca,et al.  Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy , 2012, Diabetes Care.

[10]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[11]  B. Ahrén,et al.  Gastrin Releasing Peptide (GRP): Effects on basal and stimulated insulin and glucagon secretion in the mouse , 1987, Peptides.

[12]  F. Sundler,et al.  PACAP is an islet neuropeptide which contributes to glucose-stimulated insulin secretion. , 1999, Biochemical and biophysical research communications.

[13]  M. Fineman,et al.  A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). , 2005, Clinical therapeutics.

[14]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[15]  J. Rosenstock,et al.  Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial , 2015, Diabetes Care.

[16]  J. Sturis,et al.  Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. , 2002, Diabetes care.

[17]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[18]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[19]  S. Al-Sabah,et al.  Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. , 2014, European journal of pharmacology.

[20]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[21]  J. Holst,et al.  Feedback suppression of meal‐induced glucagon‐like peptide‐1 (GLP‐1) secretion mediated through elevations in intact GLP‐1 caused by dipeptidyl peptidase‐4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment , 2016, Diabetes, obesity & metabolism.

[22]  J. Holst,et al.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  M. Zdravkovic,et al.  The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men , 2002, Diabetologia.

[24]  M. Zdravkovic,et al.  Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase , 2010, Drug Metabolism and Disposition.

[25]  J. Holst,et al.  Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients , 2002, Diabetologia.

[26]  J. Rosenstock,et al.  Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin , 2013, Diabetes Care.

[27]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[28]  M. Nauck,et al.  Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study , 2009, International journal of clinical practice.

[29]  J. Holst,et al.  Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose , 2014, Diabetes.

[30]  J. Holst,et al.  Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade , 2014, Diabetes.

[31]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[32]  Eberhard Standl,et al.  Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. , 2004, Diabetes care.

[33]  M. Nauck,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial , 2007, Diabetes, obesity & metabolism.

[34]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[35]  Shaoping Deng,et al.  Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.

[36]  M. Davies,et al.  Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes * , 2008, Diabetes, obesity & metabolism.

[37]  J. Holst,et al.  Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors , 2015, Diabetes, obesity & metabolism.

[38]  P. J. Larsen,et al.  GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical development , 2001 .

[39]  Abstract , 1952 .

[40]  K. Yoon,et al.  A randomized non‐inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[41]  L. Bardram,et al.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. , 2014, Endocrinology.

[42]  J. Holst,et al.  Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.